Liraglutide With or Without Metformin Ameliorates Liver Function and Fatty Liver in Obese Patients with Type 2 Diabetes Mellitus

被引：0

作者：

Iwao, Tadashi ^{[1
]}

Sakai, Kenji ^{[1
]}

Ando, Eiji ^{[1
]}

机构：

[1] Iwao Hosp, Dept Med, 2-4-29 Tansou, Hita 8770012, Japan

来源：

JOURNAL OF DIABETES & METABOLISM | 2015年 / 6卷 / 09期

关键词：

Liraglutide; Liver function; Type 2 diabetes mellitus; Visceral adipose tissue;

D O I：

10.4172/2155-6156.1000598

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To evaluate efficacy of 24 weeks administration of liraglutide with or without metformin on liver parameters<visceral adipose tissue (VAT) area and liver-to-spleen attenuation (L/S) ratio between non-obese and obese patients with type 2 diabetes mellitus. Methods: A total of 57 patients with type 2 diabetes: non-obese group (N= 30) and obese group (N= 27) were enrolled. HbA1c<body weight<aspartate aminotransferase (AST)<alanine aminotransferase (ALT)<and VAT area and L/S ratio were measured before and after the treatment. Results: In the two groups<sustained and significant reductions were observed in HbA1c<and body weight. A similar reduction was observed in AST and ALT level<but the change was greater in obese group than in non-obese group (p< 0.05<p< 0.05<respectively). Although reduction in VAT area did not differ in both groups<the change of L/S ratio was greater in obese subjects than in non-obese subjects (p< 0.05). In all patients<multiple regression analysis showed that the reduction in ALT was significantly correlated with the reduction in VAT area (95% confidential interval 0.15-0.69; p< 0.01)<whereas either the changes in HbA1c<body weight and L/S ratio or the presence of dyslipidemia were not significant. Conclusion: Liraglutide with or without metformin ameliorates liver function and reduces fat tissue on the liver particularly in obese patients with type 2 diabetes mellitus. The potential mechanism might be due to decreases VAT area by liraglutide with or without metformin.

引用

页数：6

共 24 条

[1] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].

Agerso, H ;

Jensen, LB ;

Elbrond, B ;

Rolan, P ;

Zdravkovic, M .

DIABETOLOGIA, 2002, 45 (02) :195-202

[2] From fatty liver to fibrosis: A tale of "second hit" [J].

Basaranoglu, Metin ;

Basaranoglu, Gokcen ;

Senturk, Hakan .

WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (08) :1158-1165

[3] Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes [J].

Basu, A ;

Jensen, MD ;

McCann, F ;

Mukhopadhyay, D ;

Joyner, MJ ;

Rizza, RA .

DIABETES CARE, 2006, 29 (03) :510-514

[4] Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study [J].

Bedogni, G ;

Miglioli, L ;

Masutti, F ;

Tiribelli, C ;

Marchesini, G ;

Bellentani, S .

HEPATOLOGY, 2005, 42 (01) :44-52

[5] Fatty liver disease in diabetes mellitus [J].

Bhatt, Harikrashna ;

Smith, Robert .

HEPATOBILIARY SURGERY AND NUTRITION, 2015, 4 (02) :101-108

[6] Incretin-based therapies in type 2 diabetes mellitus [J].

Chia, Chee W. ;

Egan, Josephine M. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10) :3703-3716

[7]

Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x

[8] Steatohepatitis: A tale of two "hits"? [J].

Day, CP ;

James, OFW .

GASTROENTEROLOGY, 1998, 114 (04) :842-845

[9] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[10] Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans [J].

Flint, A ;

Raben, A ;

Astrup, A ;

Holst, JJ .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (03) :515-520

← 1 2 3 →